Eradication of leukemia stem cells as a new goal of therapy in leukemia

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 340-344

  Ravandi, Farhad ^a   Estrov, Zeev ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYTOTOXIC AGENT; PARTHENOLIDE;

ANIMAL CELL; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; CELL RENEWAL; CELL STRUCTURE; CELL SURFACE; CHROMOSOME ABERRATION; CLONOGENESIS; EPIGENETICS; ERADICATION THERAPY; HEMATOPOIETIC STEM CELL; LEUKEMIA; LEUKEMIA RELAPSE; LEUKEMIC STEM CELL; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; TUMOR STEM CELLS;

EID: 31544456409     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1879     Document Type: Review

References (85)

1. Dick JE. Stem cells: self-renewal writ in blood. Nature 2003;423:231-3.
2. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene 2004;23:7164-77.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
5. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004;5:738-43.
6. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67.
7. Korbling M, Estrov Z. Adult stem cells for tissue repair-a new therapeutic concept? N Engl J Med 2003;349:570-82.
8. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17:3029-35.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
11. McCulloch EA, Howatson AF, Buick RN, Minden MD, Izaguirre CA. Acute myeloblastic leukemia considered as a clonal hemopathy. Blood Cells 1979;5:261-82.
12. Fialkow PJ, Singer JW, Raskind WH, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987;317:468-73.
13. LapidotT, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
14. 3H-thymidine for 8 or 10 days. Cancer 1970;26:1-19.
15. Wantzin GL. Nuclear labelling of leukaemic blast cells with tritiated thymidine triphosphate in 35 patients with acut leukaemia. Br J Haematol 1977;37:475-82.
16. Till JE, McCulloch EA, Siminovitch L. A stochastic model of stem cell proliferation, based on the growth of spleen colony-forming cells. Proc Natl Acad Sci U S A 1964;51:29-36.
17. Korn AP, Henkelman RM, Ottensmeyer FP, Till JE. Investigations of a stochastic model of haemopoiesis. Exp Hematol 1973;1:362-75.
18. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A 2003;100 Suppl 1:11842-9.
19. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-5.
20. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994;94:1383-9.
21. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 1999;93:2755-9.
22. Domen J, Weissman IL. Self-renewal, differentiation or death: regulation and manipulation of hematopoietic stem cell fate. Mol Med Today 1999;5:201-8.
23. Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000;287:1442-6.
24. Morrison SJ, Uchida IM, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 1995;11:35-71.
25. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-806.
26. Kania G, Corbeil D, Fuchs J, et al. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. Stem Cells 2005;23:791-804.
27. Bornhauser M, Eger L, Oelschlaegel U, et al. Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells. Leukemia 2005;19:161-5.
28. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005;121:1109-21.
29. Storms RW, Trujillo AP, Springer JB, et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 1999;96:9118-23.
30. Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004;104:1648-55.
31. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997;89:3104-12.
32. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000;28:660-71.
33. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor α chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000;14:1777-84.
34. Brendel C, Mohr B, Schimmelpfennig C, et al. Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias. Leukemia 1999;13:1770-5.
35. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003;423:409-14.
36. Terpstra W, Prins A, Ploemacher RE, et al. Longterm leukemia-initiating capacity of a CD34- sub-population of acute myeloid leukemia. Blood 1996;87:2187-94.
37. Grimwade D, Enver T. Acute promyelocytic leukemia: where does it stem from? Leukemia 2004;18:375-84.
38. Phillips RL, Ernst RE, Brunk B, et al. The genetic program of hematopoietic stem cells. Science 2000;288:1635-40.
39. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002;298:601-4.
40. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002;298:597-600.
41. Zipori D. The nature of stem cells: state rather than entity. Nat Rev Genet 2004;5:873-8.
42. Smith LJ, Curtis JE, Messner HA, Senn JS, Furthmayr H, McCulloch EA. Lineage infidelity in acute leukemia. Blood 1983;61:1138-45.
43. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002;21:3295-313.
44. Stein MI, Zhu J, Emerson SG. Molecular pathways regulating the self-renewal of hematopoietic stem cells. Exp Hematol 2004;32:1129-36.
45. Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. Blood 1999;93:2760-70.
46. Lecuyer E, Hoang T. SCL: from the origin of hematopoiesis to stem cells and leukemia. Exp Hematol 2004;32:11-24.
47. Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001;20:5660-79.
48. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002;99:15-23.
49. de Guzman CG, Warren AJ, Zhang Z, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 2002;22:5506-17.
50. Zhu J, Giannola DM, Zhang Y, Rivera AJ, Emerson SG. NF-Ycooperates with USF1/2 to induce the hematopoietic expression of HOXB4. Blood 2003;102:2420-7.
51. Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev 1995;9:1753-65.
52. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
53. Lawrence HJ, Rozenfeld S, Cruz C, et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 1999;13:1993-9.
54. Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT-WNTsituation. Nat Rev lmmunol 2005:5:21-30.
55. Duncan AW, Rattis FM, DiMascio LN, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005;6:314-22.
56. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
57. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versusT lineage determination. Immunity 1999;11:299-308.
58. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-61.
59. van der Lugt NM, Alkema M, Berns A, Deschamps J. The Polycomb-group homolog Bmi-1 is a regulator of murine Hox gene expression. Mech Dev 1996;58:153-64.
60. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54.
61. Lessard J, Baban S, Sauvageau G. Stage-specific expression of polycomb group genes in human bone marrow cells. Blood 1998;91:1216-24.
62. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003;423:302-5.
63. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003;423:255-60.
64. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001;2:172-80.
65. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003;101:3142-9.
66. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
67. Konopleva M, ZhaoS, Hu W.etl.Theanti-apoptotic genes BcI-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002;118:521-34.
68. Chaudhary PM, Roninson IB. Expression and actinity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
69. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
70. Scharenberg CW, Harkey MA. Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002:99:507-12.
71. Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34 (+) CD38 (-) progenitor cells from patients with acutemyeloid leukemia. Blood 2001;97:3882-9.
72. Guan Y, Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 2000;14:2135-41.
73. Ailles LE, Humphries RK, Thomas TE, Hogge DE. Retrovtral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice. Exp Hematol 1999;27:1609-20.
74. Terpstra W, Ploemacher RE, Prins A, et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood 1996;88:1944-50.
75. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301-7.
76. Holyoake T Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999;94:2056-64.
77. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093-8.
78. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-20.
79. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32.
80. Jordan CT, Guzman ML Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 2004;23:7178-87.
81. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002;99:16220-5.
82. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005;105:4163-9.
83. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires P13 kinase activation. Blood 2003;102:972-80.
84. Tani T, Ylanne J, Virtanen I. Expression of megakaryocytic and erythroid properties in human leukemic cells. Exp Hematol 1996;24:158-68.
85. Blair A, Pamphilon DH. Leukaemic stem cells. Transfus Med 2003;13:363-75.